Liminatus Pharma regains Nasdaq minimum bid price compliance after 1-for-50 reverse split

Nasdaq had flagged Liminatus Pharma on Jan. 15, 2026 for 30 straight business days below $1.00. After a 1-for-50 reverse split effective Aug. 20, 2026, Nasdaq confirmed compliance based on 13 consecutive sessions above $1.00 from Aug. 21 to Sept. 9, and moved the shares to the Nasdaq Capital Market effective Aug. 4 with a Sept. 3 deadline.